
Tilray Brands today announced that Aphria RX GmbH has received a trading license, which will allow it to sell and distribute a range of medical cannabis products to pharmacies, hospitals, and medical wholesalers throughout Germany.
"This milestone of Aphria RX obtaining both its new cultivation license as well as its trading license further expands Tilray's leadership in medical cannabis research, cultivation, production and distribution in Germany and once again proves our commitment to be one of the most responsible, trusted and market leading cannabis companies in the world with a portfolio of innovative and high-quality products that address the needs of patients. We remain dedicated to advocating for responsible cannabis regulations, education and research and accessibility to high-quality medical cannabis," said Denise Faltischek, Chief Strategy Officer and Head of International at Tilray.
With both cannabis cultivation and trade licenses, Tilray is now in a position to fully leverage the growing market opportunity in Germany, further expanding Tilray's position as a global leader in cannabis research, cultivation, production, and distribution.